(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



TOTAL BUILDING IN Dirigo (1811 brill brill brill brill brill in dold build heild inder him biologic bot in diction in be

(43) International Publication Date 15 July 2004 (15.07.2004)

(10) International Publication Number WO 2004/058223 A1

(51) International Patent Classification ⁷ :	A61K 9/16	60/435,495 60/435,505	20 December 2002 (20.12.2002) 20 December 2002 (20.12.2002)	
(21) International Application Number: PCT/0	JS2003/041391	60/450,722 60/454,997	28 February 2003 (28.02.2003) 14 March 2003 (14.03.2003)	

(22) International Filing Date:

22 December 2003 (22.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

			Ū
(30)	Priority Data:		
	60/435,163	20 December 2002 (20.12.2002)	US
	60/435,416	20 December 2002 (20.12.2002)	US
	60/435,445	20 December 2002 (20.12.2002)	US
	60/435,415	20 December 2002 (20.12.2002)	US
	60/435,488	20 December 2002 (20.12.2002)	US
	60/435,449	20 December 2002 (20.12.2002)	US
	60/435,447	20 December 2002 (20.12.2002)	US
	60/435,506	20 December 2002 (20.12.2002)	US
	60/435,507	20 December 2002 (20.12.2002)	US
	60/435,496	20 December 2002 (20.12.2002)	US
	60/435,075	20 December 2002 (20.12.2002)	US
	60/435,423	20 December 2002 (20.12.2002)	US
	60/435,336	20 December 2002 (20.12.2002)	US
	60/435,630	20 December 2002 (20.12.2002)	US
	60/435,372	20 December 2002 (20.12.2002)	US
	60/435,106	20 December 2002 (20.12.2002)	US
	60/435,388	20 December 2002 (20.12.2002)	US
	60/435,632	20 December 2002 (20.12.2002)	US
	60/435,557	20 December 2002 (20.12.2002)	US
	60/435,558	20 December 2002 (20.12.2002)	US
	60/435,132	20 December 2002 (20.12.2002)	US
	60/435,497	20 December 2002 (20.12.2002)	US
	60/435,494	20 December 2002 (20.12.2002)	US
	60/435,508	20 December 2002 (20.12.2002)	US
	60/435,501	20 December 2002 (20.12.2002)	US
	60/435,565	20 December 2002 (20.12.2002)	US
	60/435,038	20 December 2002 (20.12.2002)	US
	60/435,037	20 December 2002 (20.12.2002)	US
	60/435,162	20 December 2002 (20.12.2002)	US
	60/435,338	20 December 2002 (20.12.2002)	US
	60/435,509	20 December 2002 (20.12.2002)	US

(71) Applicant (for all designated States except US): ST. JAMES ASSOCIATES LLC/FABER RESEARCH SERIES [US/US]; 135 East Holly Street, Apartment 408, Pasadena, CA 91103 (US).

(72) Inventor; and

- (75) Inventor/Applicant (for US only): SMITH, Thomas, J. [CA/US]; 135 East Holly Street, Apt. 408, Pasadena, CA 91103 (US).
- (74) Agents: TWOMEY, Michael, J. et al.; Hale and Dorr LLP, 60 State Street, Boston, MA 02109 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COATED PARTICLES FOR SUSTAINED-RELEASE PHARMACEUTICAL ADMINISTRATION

(57) Abstract: Coated microparticles for sustained-release of an active pharmaceutical ingredient after parenteral administration, and methods of producing such coated microparticles, are provided. The coated microparticles comprise core particles of an active pharmaceutical ingredient and a first polymeric coating on the core particles. The first polymeric coating is permeable to the active pharmaceutical ingredient forms a saturated solution within the coated microparticle, resulting in pseudo-zero-sustained release period. A second polymeric coating can be employed to add mechanical support or as a rate-controlling element.